浏览全部资源
扫码关注微信
XRCC1 基因的DNA甲基化在胃癌患者铂类药物化疗疗效中的预测作用XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer- 重庆医科大学学报 2022年47卷第5期 页码：563-567
- 作者机构：
1.上海交通大学医学院附属第九人民医院 消化内科，上海 200011
2.上海交通大学医学院附属第九人民医院 普外科，上海 200011
3.上海交通大学医学院附属第九人民医院 病理科，上海 200011
- 作者简介：
王萍，Email：lily7410@163.com，研究方向：消化道疾病。
严华，Email：luoxia88881@sina.com。
- 基金信息：
DOI：10.13406/j.cnki.cyxb.003029
中图分类号： R735.2纸质出版日期：2022-05-28，
收稿日期：2021-08-31，
扫 描 看 全 文
王萍, 郭美, 王兵, 等.
XRCC1 基因的DNA甲基化在胃癌患者铂类药物化疗疗效中的预测作用[J]. 重庆医科大学学报, 2022,47(5):563-567.Ping Wang, Mei Guo, Bing Wang, et al.
XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):563-567.王萍, 郭美, 王兵, 等.
XRCC1 基因的DNA甲基化在胃癌患者铂类药物化疗疗效中的预测作用[J]. 重庆医科大学学报, 2022,47(5):563-567. DOI： 10.13406/j.cnki.cyxb.003029.Ping Wang, Mei Guo, Bing Wang, et al.
XRCC1 gene DNA methylation on predicting the efficacy of oxaliplatin-based chemotherapy in patients with gastric cancer[J]. Journal of Shanxi Agricultural Sciences, 2022,47(5):563-567. DOI： 10.13406/j.cnki.cyxb.003029.
摘要
目的：
2
探讨
XRCC1
基因的DNA甲基化对接受含奥沙利铂方案辅助化疗胃癌患者的疗效预测价值。
方法：
2
经病理确诊的胃癌患者116例，接受奥沙利铂和氟尿嘧啶类联合的方案化疗至少6周期。采用亚硫酸氢盐测序法对胃癌手术标本进行
XRCC1
基因的甲基化水平检测，并分析其与胃癌患者化疗疗效的相关性。
结果：
2
不同性别、年龄、是否淋巴结转移、不同肿瘤直径、不同分化程度、是否接受辅助化疗的胃癌患者之间
XRCC1
基因的DNA甲基化水平差异均无统计学意义（
P
>
0.05）。术后接受化疗和未接受化疗的胃癌患者的平均生存期分别为（42.82±3.57）个月和（25.68±4.90）个月，接受化疗的胃癌患者生存期更长（
χ
2
=7.208，
P
=0.07）。化疗有效组的平均甲基化率为51.60%，化疗无效组为38.31%，2组比较差异具有统计学意义（
P
<
0.05）。
结论：
2
XRCC1
基因的DNA甲基化率与奥沙利铂的敏感性呈正相关，是潜在的预测胃癌患者化疗有效性及预后的分子标记物。
Abstract
Objective
:
2
To investigate the value of
XRCC1
gene DNA methylation in predicting the efficacy of oxaliplatin-based adjuvant chemotherapy in patients with gastric cancer.
Methods
:
2
A total of 116 patients with gastric cancer received at least 6 cycles of combination chemotherapy of oxaliplatin and fluorouracil. Bisulfite sequencing was used to analyze the methylation of
XRCC1
gene in gastric cancer surgical specimens
and the correlation with the efficacy of chemotherapy in patients with gastric cancer were also analyzed.
Results
:
2
There was no statistically significant difference in the average methylation rates of
XRCC1
gene among gastric cancer patients with different gender
age
lymph node metastasis
tumor diameters
differentiation
and whether they received adjuvant chemotherapy (
P
>
0.05) . The average survival time of gastric cancer patients receiving chemotherapy and not receiving chemotherapy were (42.82±3.57) months and (25.68±4.90) months
respectively. The survival time of gastric cancer patients receiving chemotherapy was longer (
χ
2
=7.208
P
=0.007) . The average methylation rate of chemotherapy effective group was 51.60%
and that of chemotherapy ineffective group was 38.31%
with significant differences between the two groups (
P
<
0.05) .
Conclusion
:
2
The DNA methylation rate of
XRCC1
gene is positively correlated with the sensitivity of oxaliplatin
which is a potential molecular marker to predict the efficacy and prognosis of chemotherapy in patients with gastric cancer.
关键词
胃肿瘤化学疗法辅助甲基化预后
Keywords
stomach neoplasmchemotherapyadjuvantmethylationprognosis
references
张思维, 杨之洵, 郑荣寿, 等. 2013年中国胃癌发病与死亡分析[J]. 中华肿瘤杂志, 2017, 39(7): 547-552.
Zhang SW, Yang ZX, Zheng RS, et al. Incidence and mortality of stomach cancer in China, 2013[J]. Chin J Oncol, 2017, 7(39): 547-552.
王少明, 郑荣寿, 张思维, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521.
Wang SM, Zheng RS, Zhang SW, et al. Epidemiological characteristics of gastric cancer in China, 2015[J]. Chin J Epidemiol, 2019, 40(12): 1517-1521.
国家卫生健康委员会. 胃癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9(3): 118-144.
National Health Commission. Gastric Cancer Diagnosis and Treatment Standards (2018)[J]. J Dig Med Imageology Electron Ed, 2019, 9(3): 118-144.
Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD004064.
Afifah NN, Diantini A, Intania R, et al. Genetic polymorphisms and the efficacy of platinum-based chemotherapy: review[J]. Pharmgenomics Pers Med, 2020, 13: 427-444.
Ortiz-Barahona V, Joshi RS, Esteller M. Use of DNA methylation profiling in translational oncology[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.011http://doi.org/10.1016/j.semcancer.2020.12.011.
Uddin MS, Mamun AA, Alghamdi BS, et al. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.015http://doi.org/10.1016/j.semcancer.2020.12.015.
Brown R, Curry E, Magnani L, et al. Poised epigenetic states and acquired drug resistance in cancer[J]. Nat Rev Cancer, 2014, 14(11): 747-753.
中华人民共和国国家卫生和计划生育委员会. 胃癌规范化诊疗指南(试行)[J]. 中国医学前沿杂志(电子版), 2013, 5(8): 29-36.
State Health and Family Planning Commission of the people's Republic of China. Gastric Cancer Diagnosis and Treatment Standards (Trial)[J]. Chin J Front Med Sic Electron Version, 2013, 5(8): 29-36.
Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment[J]. Annu Rev Med, 2003, 54: 437-452.
Fujii N. Potential strategies to target protein-protein interactions in the DNA damage response and repair pathways[J]. J Med Chem, 2017, 60(24): 9932-9959.
Wang P, Tang JT, Peng YS, et al. XRCC1 downregulated through promoter hypermethylation is involved in human gastric carcinogenesis[J]. J Dig Dis, 2010, 11(6): 343-351.
刘源. ERCC1、XRCC1表达对晚期NSCLC患者化疗疗效与预后的影响[J]. 实用癌症杂志, 2016, 31(9): 1396-1398.
Liu Y. Effects of ERCC1 and XRCC1 expression on the efficacy and prognosis of chemotherapy for advanced NSCLC[J]. Pract J Cancer, 2016, 31(9): 1396-1398.
Tudek B. Base excision repair modulation as a risk factor for human cancers[J]. Mol Aspects Med, 2007, 28(3/4): 258-275.
Zhao W, Hu LM, Xu JL, et al. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2013, 71(5): 1287-1295.
Lv HY, Li QC, Qiu WS, et al. Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer[J]. Pathol Oncol Res, 2012, 18(4): 1009-1014.
Zhai XH, Huang J, Wu FX, et al. Impact of XRCC1, GSTP1, and GSTM1 polymorphisms on the survival of ovarian carcinoma patients treated with chemotherapy[J]. Oncol Res Treat, 2016, 39(7/8): 440-446.
Zhang Z, Xiang Q, Mu GY, et al. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: a systematic review and MOOSE-compliant meta-analysis[J]. Medicine (Baltimore), 2018, 97(45): e12996.
Oleksiewicz U, Machnik M. Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome[J]. Semin Cancer Biol, 2020[Epub ahead of print]. doi: 10.1016/j.semcancer.2020.12.014http://doi.org/10.1016/j.semcancer.2020.12.014.
Cheng Y, He C, Wang MN, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials[J]. Signal Transduct Target Ther, 2019, 4: 62.
Matei D, Fang F, Shen CY, et al. Epigenetic resensitization to platinum in ovarian cancer[J]. Cancer Res, 2012, 72(9): 2197-2205.
Yu SL, Ao Z, Wu Y, et al. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer[J]. Cell Prolif, 2020, 53(11): e12924.
Cervena K, Siskova A, Buchler T, et al. Methylation-based therapies for colorectal cancer[J]. Cells, 2020, 9(6): 1540.
Fazal Z, Singh R, Fang F, et al. Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours[J]. Epigenetics, 2021, 16(10): 1071-1084.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- XML下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
